Pharmaceuticals

Global Nivolumab Market Valuation and Growth Prospects: $1.59 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nivolumab market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Nivolumab Market Size?

The nerve growth factor market has experienced robust expansion in recent years. Projections indicate an increase from $1.11 billion in 2024 to $1.19 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. This historical growth can be linked to several factors, including a higher incidence of traumatic brain injuries, the growing prevalence of neurodegenerative diseases, increased investment in research and development, greater awareness regarding nerve regeneration therapies, and a rising occurrence of peripheral neuropathy.

The nerve growth factor market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $1.59 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period is primarily driven by an escalation in demand for biopharmaceuticals, an increased prevalence of autoimmune neurological disorders, a heightened focus on neuroinflammation research, rising investment in AI-driven drug discovery initiatives, and a growing consumer demand for NGF-based therapies. Significant trends influencing the market over this period include advancements in biotechnology, the adoption of personalized medicine approaches, the introduction of innovative drug delivery systems, crucial regulatory approvals, and the ongoing development of nerve growth factor (NGF) antibodies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22070&type=smp

What Core Market Drivers Are Expanding The Nivolumab Industry?

The rising occurrence of neurological conditions is projected to boost the expansion of the nerve growth factor market in the future. These conditions are medical ailments impacting the brain, spinal cord, and nerves, resulting from structural, biochemical, or electrical irregularities. The growing incidence of neurological disorders stems from an aging global population and advancements in diagnostic methods. Improved diagnostic technology facilitates better detection and reporting of these conditions, leading to higher recorded rates. Nerve growth factor (NGF) is vital for the upkeep, survival, and renewal of neurons, positioning it as an essential element in managing the widespread nature of neurological disorders through fostering neural repair and potentially retarding disease progression. For example, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that dementia (a neurological disorder) cases in Australia are anticipated to climb from approximately 411,100 in 2023 to 849,300 by 2058. Consequently, the increasing prevalence of neurological disorders is propelling the growth of the nerve growth factor market.

What Segment Insights Are Highlighted In The Nivolumab Market Report?

The nerve growth factor market covered in this report is segmented –

1) By Type: Alpha-Nerve Growth Factor (NGF), Beta-Nerve Growth Factor (NGF), Gamma-Nerve Growth Factor (NGF), Other Types

2) By Agents: Cenegermin, Other Agents

3) By Indication: Neurodegenerative Disorders, Spinal Cord Injuries, Eye Disorders, Epithelial Diseases, Tissue Healing, Other Indications

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Alpha-Nerve Growth Factor (α-NGF): Natural Alpha-NGF, Recombinant Alpha-NGF, Synthetic Alpha-NGF, Alpha-NGF For Research Applications

2) By Beta-Nerve Growth Factor (β-NGF): Human Beta-NGF, Animal-Derived Beta-NGF, Recombinant Beta-NGF, Therapeutic Beta-NGF, Research-Grade Beta-NGF

3) By Gamma-Nerve Growth Factor (γ-NGF): Natural Gamma-NGF, Recombinant Gamma-NGF, Synthetic Gamma-NGF, Gamma-NGF for Neurodegenerative Research

4) Other Types: Hybrid NGF Molecules, NGF Mimetics, NGF Gene Therapy-Based Products, NGF-Infused Biomaterials

Which Notable Trends Are Transforming The Nivolumab Market Outlook?

Leading companies in the nerve growth factor market are concentrating on developing sophisticated products, such as nerve growth factor (NGF) monoclonal antibodies, to inhibit NGF. Their objective is to deliver effective pain alleviation. An NGF monoclonal antibody functions as a biological drug that targets and neutralizes nerve growth factor (NGF) to impede receptor interaction, thereby diminishing pain and nerve inflammation. It aids in managing pain signaling and ensuring nerve cell survival. As an illustration, in February 2022, Akeso, Inc., a China-based biopharmaceutical company, introduced AK115, a humanized IgG1 monoclonal antibody that secured approval from China’s National Medical Products Administration to commence clinical trials for pain treatment, including cancer pain. AK115 is formulated to block NGF interactions with receptors, aiming to relieve pain while offering enduring safety, non-addictiveness, and enhanced efficacy for cancer patients resistant to opioids. This cutting-edge analgesic seeks to provide sustained, non-addictive pain relief, especially for opioid-resistant cancer patients, improving their overall quality of life.

Which Firms Are Driving Innovation Within The Nivolumab Market?

Major companies operating in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompé farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nerve-growth-factor-global-market-report

What Regional Trends Are Shaping Growth In The Nivolumab Market?

Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in the nerve growth factor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=22070&type=smp

Browse Through More Reports Similar to the Global Nivolumab Market 2025, By The Business Research Company

Nerve Repair And Regenerative Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Optic Nerve Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795